8-K: RenovoRx Reports 2025 Revenue, TIGeR-PaC Trial on Track

RenovoRx announced its full year 2025 financial results, reporting $1.1 million in RenovoCath revenue and progress in its Phase III TIGeR-PaC trial, alongside a strengthened balance sheet.

Summary

• Generated $1.1 million in RenovoCath revenue for the full year 2025, its first full year of commercialization, a significant increase from $43,000 in 2024.
• The Phase III TIGeR-PaC trial is on track for enrollment completion by mid-2026, with final data anticipated in 2027.
• As of March 24, 2026, 104 patients have been randomized in the TIGeR-PaC trial, with 72 events (deaths) observed, targeting a minimum of 114 randomized patients.
• The balance sheet was strengthened with $13 million cash on hand as of March 30, 2026, following a $10 million gross proceeds ($9.2 million net) private placement.
• Commercial infrastructure, including a sales and marketing team, was built out in the fourth quarter of 2025.
• As of February 27, 2026, 12 U.S. cancer centers are actively utilizing RenovoCath, with 21 additional centers in evaluation or activation preparation, tripling the near-term pipeline compared to Q1 2025.
• Mark Voll was appointed as Chief Financial Officer in February 2026, and the RenovoCath Medical Advisory Board (MAB) was established in the same month.
• Net loss for 2025 was approximately $11.2 million, compared to $8.8 million in 2024.
• Research and development expenses increased to $6.3 million in 2025 from $6.0 million in 2024, primarily due to the TIGeR-PaC trial and next-generation device development.
• Selling, general, and administrative expenses increased to $7.0 million in 2025 from $5.0 million in 2024, driven by commercial infrastructure buildout.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, reflecting strong initial commercial traction for RenovoCath, solid progress in a pivotal Phase III trial, and a significantly strengthened balance sheet, despite an increased net loss.

Positives

• RenovoCath generated $1.1 million in revenue in its first full year of commercialization (2025), a substantial increase from $43,000 in 2024, reflecting strong initial physician adoption.
• The Phase III TIGeR-PaC trial is on track for enrollment completion by mid-2026, with 104 out of a minimum of 114 patients randomized as of March 24, 2026.
• The independent Data Monitoring Committee recommended continuing the TIGeR-PaC study without modification after the second interim analysis, indicating confidence in the trial's potential for a positive outcome.
• Successfully closed an oversubscribed private placement, raising $10 million gross ($9.2 million net) and significantly strengthening cash on hand to $13 million.
• Commercial infrastructure, including a sales and marketing team, was built out in Q4 2025, positioning the company for scaling in 2026.
• The number of active U.S. cancer centers utilizing RenovoCath grew to 12, with a pipeline of 21 additional centers, tripling the near-term pipeline compared to Q1 2025.
• The company appointed an experienced Chief Financial Officer, Mark Voll, and established a Medical Advisory Board to support commercial growth and clinical guidance.
• Plans to transition 17 TIGeR-PaC trial centers to commercial customers for RenovoCath in the second half of 2026 after enrollment completion.
• The estimated initial total addressable market (TAM) for RenovoCath as a stand-alone device is approximately $400 million peak annual U.S. sales opportunity, with multi-billion-dollar potential as the platform expands.

Negatives

• Net loss increased to approximately $11.2 million for the year ended December 31, 2025, compared to $8.8 million in the prior year.
• Selling, general, and administrative expenses increased significantly to $7.0 million in 2025 from $5.0 million in 2024, primarily due to the buildout of commercial infrastructure.
• Research and development expenses increased to $6.3 million in 2025 from $6.0 million in 2024, reflecting continued investment in the TIGeR-PaC trial and device development.

Risks

• The exploration of commercial opportunities for the TAMP technology may not lead to viable, revenue-generating operations.
• Circumstances could adversely impact the ability to efficiently utilize cash resources on hand or raise additional funding.
• Uncertainty regarding the timing, progress, and potential results (including interim analyses) of preclinical studies, clinical trials, and research programs.
• Interim results may not be predictive of the outcome of clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval.
• Applicable regulatory authorities may disagree with the interpretation of data, research, and clinical development plans and timelines, and the regulatory process for product candidates.
• The ability to use and expand the therapy platform to build a pipeline of product candidates.
• The ability to advance product candidates into, and successfully complete, clinical trials.
• The timing or likelihood of regulatory filings and approvals.
• Estimates of the number of patients who suffer from the diseases being targeted and the number of patients that may enroll in clinical trials may be inaccurate.
• The commercialization potential of product candidates, if approved, is uncertain.
• The ability and potential to successfully manufacture and supply product candidates for clinical trials and for commercial use, if approved.
• Future strategic arrangements and/or collaborations and the potential benefits of such arrangements.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing, and the ability to obtain additional capital.
• The sufficiency of existing cash and cash equivalents to fund future operating expenses and capital expenditure requirements.
• The ability to retain the continued service of key personnel and to identify, hire, and retain additional qualified personnel.
• The implementation of strategic plans for the business and product candidates.
• The scope of protection the company is able to establish and maintain for intellectual property rights, including its therapy platform, product candidates, and research programs.
• The ability to contract with third-party suppliers and manufacturers and their ability to perform adequately.
• The pricing, coverage, and reimbursement of product candidates, if approved.
• Developments relating to competitors and the industry, including competing product candidates and therapies.

Future Outlook

The company anticipates completing enrollment for its Phase III TIGeR-PaC trial by mid-2026, with final data expected in 2027. It aims to drive significant commercial growth for RenovoCath in 2026 and beyond, leveraging its established commercial infrastructure and strengthened balance sheet to achieve important milestones, including breakeven operations and trial data. The company also plans to transition 17 TIGeR-PaC trial centers to commercial customers in the second half of 2026.

Management Comments

• "2025 marked a key year as it was our first full year of RenovoCath commercialization, generating over $1 million in revenue and reflecting strong initial physician adoption and demand in a handful of active commercial cancer centers." Shaun Bagai, CEO.
• "We also learned many valuable lessons to finalize our go-to-market strategy that we are implementing and building out a team to drive commercial growth in 2026 and beyond." Shaun Bagai, CEO.
• "We exited the year with a strong understanding of the market and a clear strategy supported by a focused and agile sales and marketing team." Shaun Bagai, CEO.
• "We strongly believe we now have the funding, business plan, leadership, and infrastructure to propel execution across all of our activities as we drive towards important milestones, including breakeven operations and trial data." Shaun Bagai, CEO.
• "Our pivotal Phase III TIGeR-PaC trial, which remains on track for full enrollment in the near term and with final results anticipated next year." Shaun Bagai, CEO.
• "Our study protocol requires us to advance a minimum of 114 patients to randomization, so we are really in the home stretch of this trial." Shaun Bagai, CEO.
• "Our goal is to transition the 17 cancer centers that have used RenovoCath as part of the TIGeR-PaC trial to commercial customers for RenovoCath in the second half of 2026 after completion of TIGeR-PaC enrollment." Shaun Bagai, CEO.

Industry Context

StockSavvy.ai notes that RenovoRx operates in the highly competitive and innovative field of targeted oncology, where novel drug-delivery devices like RenovoCath aim to improve efficacy and reduce systemic toxicities compared to traditional intravenous therapies. The reported revenue growth for RenovoCath, while modest, indicates early market acceptance in a niche but high-value segment of cancer treatment. The progress in the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, a disease with significant unmet medical needs, positions RenovoRx to potentially offer a new therapeutic option, aligning with the broader industry trend towards precision medicine and localized treatments. The strengthening of the balance sheet and commercial infrastructure suggests a strategic push to capitalize on this market opportunity.

Comparison to Industry Standards

• The company's RenovoCath device is positioned in the targeted drug-delivery market for solid tumors, specifically pancreatic cancer. While direct comparable revenue figures for similar early-stage, specialized medical devices are not provided in the filing, the reported $1.1 million in first-year commercial revenue indicates initial market penetration.
• The Phase III TIGeR-PaC trial for intra-arterial delivery of gemcitabine (IAG) via RenovoCath for locally advanced pancreatic cancer (LAPC) addresses a challenging indication. Current standard treatments for LAPC often involve systemic chemotherapy (e.g., FOLFIRINOX or gemcitabine/nab-paclitaxel) with limited survival benefits. The trial's focus on overall survival benefit with a targeted approach aims to differentiate from existing systemic therapies.
• The independent Data Monitoring Committee's recommendation to continue the TIGeR-PaC study without modification after the second interim analysis is a positive signal, often seen as a benchmark of confidence in a trial's design and potential for a positive outcome, similar to other late-stage oncology trials.
• The estimated total addressable market (TAM) of approximately $400 million peak annual U.S. sales for RenovoCath as a stand-alone device, and a multi-billion-dollar potential with platform expansion, suggests a significant market opportunity, comparable to other specialized medical devices or orphan drug indications in oncology.

Management Changes

Corporate Governance

Related Party Transactions

• The private placement financing, which raised $10 million in gross proceeds, included insider participation.

Stakeholder Impact

• Shareholders: The capital raise and strengthened balance sheet reduce immediate dilution risk and provide funding for operations and milestones. Positive trial progress and commercial growth could increase shareholder value, though increased net loss and expenses are a concern.
• Employees: The buildout of commercial infrastructure and executive leadership team suggests growth and potential for new hires, particularly in sales and marketing.
• Customers (Cancer Centers/Physicians): Growing adoption of RenovoCath and a pipeline of new centers indicate increasing utility and satisfaction. The planned transition of trial centers to commercial customers expands the user base.
• Patients: Progress in the TIGeR-PaC trial offers hope for a new targeted therapy for locally advanced pancreatic cancer, a disease with high unmet medical needs.
• Creditors: The strengthened cash position improves the company's financial stability and ability to meet obligations.

Next Steps

• Continue to implement and build out the go-to-market strategy to drive commercial growth for RenovoCath in 2026 and beyond.
• Complete enrollment for the Phase III TIGeR-PaC trial by the middle of 2026.
• Anticipate final data from the TIGeR-PaC trial in 2027.
• Transition the 17 cancer centers that used RenovoCath in the TIGeR-PaC trial to commercial customers in the second half of 2026 after enrollment completion.
• Focus on high-volume cancer centers for commercial scaling in 2026.
• Drive towards important milestones, including breakeven operations and trial data.
• Generate new data through post-marketing registry studies in solid tumors and continued support of investigator-initiated trials (IIT) in borderline resectable and metastatic pancreatic cancer.
• Explore physician interest in other areas for the TAMP therapy platform.
• Actively explore further revenue-generating activity for RenovoCath, either on its own or in tandem with a medical device commercial partner.

Key Dates

Recommendation

The filing presents a mixed but generally positive outlook. Strong revenue growth for RenovoCath's first full commercial year and significant progress in the pivotal Phase III TIGeR-PaC trial are encouraging, supported by a strengthened balance sheet from a recent capital raise. However, the increased net loss and operating expenses reflect the costs of commercialization and R&D, which are typical for a growth-stage life sciences company but warrant caution. The stock is a "hold" as the positive developments are balanced by the ongoing need for significant investment and the inherent risks of clinical trials and commercial scale-up. Investors should monitor the TIGeR-PaC trial's final data in 2027 and the pace of RenovoCath's commercial adoption.

Keywords

RenovoRx, RNXT, RenovoCath, TIGeR-PaC, pancreatic cancer, targeted oncology, drug delivery device, Phase III trial, financial results, commercialization, medical device, life sciences, oncology, TAMP therapy, FDA-cleared, capital raise